Pancreatic Cancer Research

ResearcherMount Sinai HospitalActive in the last 2 years

Neesha C. Dhani

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0410-6932; OpenAlex author ID A5019722619. Sources: OpenAlex.

Their work

Papers
17
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2014: 1 paper · 2015: 3 papers · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 17

  1. Impact of an Inter-Professional Clinic on Pancreatic Cancer Outcomes: A Retrospective Cohort Study. Co-author DOI 10.3390/curroncol31050194↗
  2. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  3. A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.21037/jgo-22-86↗
  4. Simulated dose painting of hypoxic sub-volumes in pancreatic cancer stereotactic body radiotherapy. Co-author DOI 10.1088/1361-6560/ac215c↗
  5. Pharmacokinetic Analysis of Dynamic [18F]FAZA PET Imaging in Pancreatic Cancer Patient Co-author DOI 10.21203/rs.3.rs-39968/v1↗
  6. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2019.1588↗
  7. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adeno… Co-author DOI 10.1002/cncr.31218↗
  8. Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer. Co-author DOI 10.1007/s10897-018-0212-1↗
  9. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Co-author DOI 10.1158/1078-0432.ccr-17-2994↗
  10. Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2016.3916↗
  11. Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study. Co-author DOI 10.1136/jclinpath-2016-203947↗
  12. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. Co-author DOI 10.1038/bjc.2016.222↗
  13. Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on 18F-Fluoroazomyin Arabinoside Uptake. Co-author DOI 10.2967/jnumed.115.167650↗
  14. Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole. Co-author DOI 10.1038/bjc.2015.284↗
  15. Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/jco.2014.59.7401↗
  16. Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods. Co-author DOI 10.1245/s10434-014-4196-2↗
  17. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2014.04.008↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steve Gallinger · 9 shared papers, 2015–2024 · strength 0.71
  2. David William Hedley · 10 shared papers, 2014–2022 · strength 0.67
  3. Jennifer Jane Knox · 6 shared papers, 2016–2024 · strength 0.58
  4. Malcolm J. Moore · 7 shared papers, 2014–2024 · strength 0.47
  5. Kyaw Lwin Aung · 3 shared papers, 2018–2024 · strength 0.33
  6. Robert C. Grant · 4 shared papers, 2015–2018 · strength 0.23
  7. Edward Taylor · 2 shared papers, 2020–2021 · strength 0.22
  8. Alice Chia-Chi Wei · 2 shared papers, 2015–2024 · strength 0.21
  9. Spring Holter · 3 shared papers, 2015–2018 · strength 0.18
  10. Stefano Serra · 3 shared papers, 2015–2017 · strength 0.17
  11. Sandra Elisabeth Fischer · 2 shared papers, 2018–2022 · strength 0.17
  12. Raymond Jang · 1 shared paper, 2024 · strength 0.16
  13. Gordon Taylor Moffat · 1 shared paper, 2024 · strength 0.16
  14. Grainne Mary O'Kane · 2 shared papers, 2018–2021 · strength 0.16
  15. Eileen Mary O'Reilly · 2 shared papers, 2018–2019 · strength 0.14
  16. Ayelet Borgida · 2 shared papers, 2015–2018 · strength 0.13
  17. Daniel John Renouf · 2 shared papers, 2014–2019 · strength 0.12
  18. Sangeetha N. Kalimuthu · 2 shared papers, 2017 · strength 0.12
  19. Ting‐Yim Lee · 1 shared paper, 2020 · strength 0.12
  20. Fiona Li · 1 shared paper, 2020 · strength 0.12
  21. Rachel Anne Goodwin · 1 shared paper, 2022 · strength 0.12
  22. Lillian Siu · 1 shared paper, 2022 · strength 0.12
  23. Philippe Lucien Bedard · 1 shared paper, 2022 · strength 0.12
  24. Ahmed M. Elamir · 1 shared paper, 2021 · strength 0.10
  25. James D. Brierley · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.